A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia

Estado	**Tipo de Participantes**	**Rangos de Edad**
Interrumpido	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase I , Fase II	25
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	Si
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	seguridad, eficacia, farmacocinética	NO

Información

Identificador
2024-516641-39-00 (CTIS)

Cod. Protocolo
AB18001

Transicionado 2020-005122-28

Área terapéutica
Enfermedades [C] - Hematología [C15]|

Enfermedad investigada
Acute Myeloid Leukemia

Título Científico
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia

Justificación

No aportado

Objetivo Principal

To define the safety and tolerability of AB8939 in patients with refractory or relapsed AML and MDS by determining the dose-limiting toxicities, the maximum tolerated dose (MTD) and the recommended dose for dose expansion trial.

Variables de Evaluación Primaria

Rate of dose-limiting toxicity (DLT)

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

To determine the pharmacokinetics profile in function of dose.
To assess early efficacy.

Variables de Evaluación Secundaria

Rate and duration of composite response rate (CRc) is defined as CRc = CR + CRh + CRi + CRp
Rate of ORR
PK parameters: Tmax, Cmax, AUC0-t, AUC0-inf, t1/2, Cl, Vd, after the first administration for all patients
Response rate based on the subtype of leukemia, risk-status, and genetic abnormalities

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Patients with documented diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) based on the last version of the World Health Organization classification. Male or non-pregnant female 18 years old at the time of signing the informed consent. ECOG performance status 1 Patients not eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion Patients must have adequate organ function without severe heart, lung, liver, kidney or nervous system dysfunction or immune deficiency In the absence of rapidly progressing

disease, the interval from prior treatment to time of AB8939 administration should be at least 14 days. Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures Adequate recovery, to a maximum of Grade 1 (CTCAE V5.0) from toxicity of prior therapy. Patients are able and willing to comply with trial procedures as per protocol, including bone marrow biopsies AML patients in second, third, fourth, or fifth line of treatment, if they were eligible to high dose chemotherapy in first line. Or AML patients in second line of treatment, if they were not eligible to high dose chemotherapy in first line. Or MDS patients in second, third, fourth, or fifth line of treatment and with high risk at prognostic based on the IPSS-R scoring system. All patients should have white blood cell count <25 × 109 /l prior to initiation of venetoclax and cytoreduction prior to treatment may be required Patients must be expected to complete the treatment period, in the opinion of the investigator.

Criterios de Exclusión

Patients eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion Patients with history or evidence of renal disease such as severe renal failure defined as creatinine clearance < 30 ml/min, Patients with history or evidence of CNS disease such as epilepsy, Alzheimer's and other dementias, strokes, migraine and other headaches possibly related to brain tumor or metastasis, multiple sclerosis, Parkinson's disease, neurological infections, brain tumors, sequellae of head injuries and disorders caused by malnutrition Patients with diabetes that are not well-controlled by two oral anti-diabetic drugs or insulin with Fasting Blood Glycemia > 110mg/dl and /or HbA1c >7% Patients with vitamin B12 deficiency, or alcohol addiction Women with a positive pregnancy test Patients with positive test for active AIDS (HIV1-2 test), Hepatitis B (antigene HBs), C (PCR positive), and tuberculosis Patients with white blood cells count or circulating blasts 20,000 cells/µL with hydroxyurea at screening Patients with AST and or ALT 2.5 ULN,Total bilirubin level > 1.5 ULN (except in case of Gilberts syndrome but within the limit of 3 x ULN) Serum creatinine 1.5 ULN and Albumin <30g/l (as AB8939 has a strong plasma protein binding) Men and women of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study and 6months for women and 3 months for men; after receiving the last dose of study drug Women planning to become pregnant while on study and 6months after receiving the last dose of study drug Patients with clinically active CNS leukemia Patients under psychiatric or, protected by law under guardianship or curatorship, or in emergency situations or, prisoners or, without National Health Insurance Patients diagnosed with acute promyelocytic leukemia (M3) Patients eligible to standard of care Patients with HSCT within 100 days prior to the first administration of AB8939 Patients who are receiving any other investigational administered with the intention to treat their malignancy within 2 weeks from the last dose prior to entering the study, with the exception of hydroxyurea. Patients likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge Patients with known toxicity to venetoclax and/or to azacitidine who intend to participate in steps involving either venetoclax or/and azacitidine Patients who have received prior standard treatment within 2 weeks or those who have not recovered from adverse events due to treatment administered more than 2 weeks earlier Patients with other active malignancies are ineligible unless they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence or progression of that malignancy Women who are lactating/breastfeeding or who plan to breastfeed while on trial Patients with major surgery within 28 days prior to the first administration of AB8939 Patients with radiation therapy within 28 days prior to the first administration of AB8939 Patients with uncontrolled hypertension e.g. SBP/DBP >149/90 mmHg despite two anti-hypertensive therapy Patients with history or evidence of neuromuscular disease such as amyotrophic lateral sclerosis, muscular dystrophy, polymyositis, myasthenia gravis, dermatomyositis, sarcopenia, Patients with history or evidence of cardiovascular disease such as stroke, ischemic heart disease (myocardial infarction, acute coronary syndrome, unstable angina), heart failure (EF < 50%), conduction disorders (Second degree or third-degree atrioventricular block not successfully treated with a pacemaker, Bi-fascicular block), uncontrolled arrythmia, abnormal QT interval (QTcF > 450 ms for male and >470 ms for female patients), history of torsades de pointes, pericarditis, valvular disease that are not well-controlled

Calendario

(Última actualización: 04/08/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
28/12/2021	31/05/2022	28/07/2022	02/04/2026	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
19/03/2026	No aportado	No aportado	No aportado	No aportado

Promotor

Ab Science France

3 Avenue George V

Contact Person

Alain Moussy

033147202311

regulatoryaffairs@ab-science.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital Universitario 12 de Octubre

Glorieta de Málaga, S/N 28041 Madrid

ceic@h12o.es

917792613

Centros

Activo (15/06/2022)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Oncología

No iniciado (--/--/----)

Clinica Universidad De Navarra

Madrid

MADRID

Hematología y Hemoterapia

Activo (05/07/2022)

HOSPITAL GENERAL UNIVERSITARIO DR. BALMIS

Alicante/Alacant

ALICANTE

Oncología

No iniciado (--/--/----)

Hospital Md Anderson Cáncer Center Madrid

Madrid

MADRID

Servicio de Hematología y Hemoterapia

Activo (17/10/2022)

HOSPITAL MD ANDERSON CANCER CENTER MADRID

Madrid

MADRID

Oncología

Activo (23/09/2022)

HOSPITAL SAN PEDRO DE ALCANTARA

Cáceres

CÁCERES

Oncología

No iniciado (--/--/----)

Hospital San Pedro de Alcantara

Cáceres

CÁCERES

Servicio de Hematología y Hemoterapia

No iniciado (--/--/----)

Hospital Universitario Quirónsalud Madrid

Madrid

MADRID

Hematology

Activo (17/06/2022)

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID

Pozuelo de Alarcón

MADRID

Oncología

Activo (20/09/2022)

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO

Sevilla

SEVILLA

Oncología

No iniciado (--/--/----)

Hospital Universitario Virgen del Rocio

Sevilla

SEVILLA

Departamento de Medicina

Activo (28/07/2022)

HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE

València

VALENCIA

Oncología

Activo (31/05/2022)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Medicamentos

Venclyxto 100 mg film-coated tablets
FILM-COATED TABLET
ORAL

Código ATC: L01XX52 - VENETOCLAX
Principios Activos: N/A

Experimental

AB8939
POWDER FOR INJECTION
INTRAVENOUS INJECTION

-

Principios Activos: N/A

Huérfano

Experimental

Vidaza 25 mg/ml powder for suspension for injection
SUSPENSION FOR INJECTION
INTRAVENOUS (IV) OR SUBCUTANEOUS (SC)

Código ATC: L01BC07 - AZACITIDINA
Principios Activos: N/A

Experimental

Sin resultados

A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia

State	**Type of participants**	**Age Ranges**
Halted	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase I , Phase II	25
Results	**Low level of intervention**	**Rare disease**
No results	No	Yes
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	safety, effectiveness, pharmacokinetics	NO

Information

Identifier
2024-516641-39-00 (CTIS)

Protocol Code
AB18001

Transitioned 2020-005122-28

Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]|

Investigated Disease
Acute Myeloid Leukemia

Scientific Title
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia

Rationale

Not provided

Main Objective

To define the safety and tolerability of AB8939 in patients with refractory or relapsed AML and MDS by determining the dose-limiting toxicities, the maximum tolerated dose (MTD) and the recommended dose for dose expansion trial.

Primary Endpoints

Rate of dose-limiting toxicity (DLT)

Temporary moments of secondary assessment

Not provided

Secondary Objective

To determine the pharmacokinetics profile in function of dose.
To assess early efficacy.

Secondary Endpoints

Rate and duration of composite response rate (CRc) is defined as CRc = CR + CRh + CRi + CRp
Rate of ORR
PK parameters: Tmax, Cmax, AUC0-t, AUC0-inf, t1/2, Cl, Vd, after the first administration for all patients
Response rate based on the subtype of leukemia, risk-status, and genetic abnormalities

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Patients with documented diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) based on the last version of the World Health Organization classification. Male or non-pregnant female 18 years old at the time of signing the informed consent. ECOG performance status 1 Patients not eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion Patients must have adequate organ function without severe heart, lung, liver, kidney or nervous system dysfunction or immune deficiency In the absence of rapidly progressing

disease, the interval from prior treatment to time of AB8939 administration should be at least 14 days. Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures Adequate recovery, to a maximum of Grade 1 (CTCAE V5.0) from toxicity of prior therapy. Patients are able and willing to comply with trial procedures as per protocol, including bone marrow biopsies AML patients in second, third, fourth, or fifth line of treatment, if they were eligible to high dose chemotherapy in first line. Or AML patients in second line of treatment, if they were not eligible to high dose chemotherapy in first line. Or MDS patients in second, third, fourth, or fifth line of treatment and with high risk at prognostic based on the IPSS-R scoring system. All patients should have white blood cell count <25 × 109 /l prior to initiation of venetoclax and cytoreduction prior to treatment may be required Patients must be expected to complete the treatment period, in the opinion of the investigator.

Exclusion criteria

Patients eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion Patients with history or evidence of renal disease such as severe renal failure defined as creatinine clearance < 30 ml/min, Patients with history or evidence of CNS disease such as epilepsy, Alzheimer's and other dementias, strokes, migraine and other headaches possibly related to brain tumor or metastasis, multiple sclerosis, Parkinson's disease, neurological infections, brain tumors, sequellae of head injuries and disorders caused by malnutrition Patients with diabetes that are not well-controlled by two oral anti-diabetic drugs or insulin with Fasting Blood Glycemia > 110mg/dl and /or HbA1c >7% Patients with vitamin B12 deficiency, or alcohol addiction Women with a positive pregnancy test Patients with positive test for active AIDS (HIV1-2 test), Hepatitis B (antigene HBs), C (PCR positive), and tuberculosis Patients with white blood cells count or circulating blasts 20,000 cells/µL with hydroxyurea at screening Patients with AST and or ALT 2.5 ULN,Total bilirubin level > 1.5 ULN (except in case of Gilberts syndrome but within the limit of 3 x ULN) Serum creatinine 1.5 ULN and Albumin <30g/l (as AB8939 has a strong plasma protein binding) Men and women of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study and 6months for women and 3 months for men; after receiving the last dose of study drug Women planning to become pregnant while on study and 6months after receiving the last dose of study drug Patients with clinically active CNS leukemia Patients under psychiatric or, protected by law under guardianship or curatorship, or in emergency situations or, prisoners or, without National Health Insurance Patients diagnosed with acute promyelocytic leukemia (M3) Patients eligible to standard of care Patients with HSCT within 100 days prior to the first administration of AB8939 Patients who are receiving any other investigational administered with the intention to treat their malignancy within 2 weeks from the last dose prior to entering the study, with the exception of hydroxyurea. Patients likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge Patients with known toxicity to venetoclax and/or to azacitidine who intend to participate in steps involving either venetoclax or/and azacitidine Patients who have received prior standard treatment within 2 weeks or those who have not recovered from adverse events due to treatment administered more than 2 weeks earlier Patients with other active malignancies are ineligible unless they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence or progression of that malignancy Women who are lactating/breastfeeding or who plan to breastfeed while on trial Patients with major surgery within 28 days prior to the first administration of AB8939 Patients with radiation therapy within 28 days prior to the first administration of AB8939 Patients with uncontrolled hypertension e.g. SBP/DBP >149/90 mmHg despite two anti-hypertensive therapy Patients with history or evidence of neuromuscular disease such as amyotrophic lateral sclerosis, muscular dystrophy, polymyositis, myasthenia gravis, dermatomyositis, sarcopenia, Patients with history or evidence of cardiovascular disease such as stroke, ischemic heart disease (myocardial infarction, acute coronary syndrome, unstable angina), heart failure (EF < 50%), conduction disorders (Second degree or third-degree atrioventricular block not successfully treated with a pacemaker, Bi-fascicular block), uncontrolled arrythmia, abnormal QT interval (QTcF > 450 ms for male and >470 ms for female patients), history of torsades de pointes, pericarditis, valvular disease that are not well-controlled

Calendar

(Last Update: 04/08/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
28/12/2021	31/05/2022	28/07/2022	02/04/2026	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
19/03/2026	Not aported	Not aported	Not aported	Not aported

Sponsor

Ab Science France

3 Avenue George V

Contact Person

Alain Moussy

033147202311

regulatoryaffairs@ab-science.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Universitario 12 de Octubre

Glorieta de Málaga, S/N 28041 Madrid

ceic@h12o.es

917792613

Sites

Active (15/06/2022)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Oncología

not initialized (--/--/----)

Clinica Universidad De Navarra

Madrid

MADRID

Hematología y Hemoterapia

Active (05/07/2022)

HOSPITAL GENERAL UNIVERSITARIO DR. BALMIS

Alicante/Alacant

ALICANTE

Oncología

not initialized (--/--/----)

Hospital Md Anderson Cáncer Center Madrid

Madrid

MADRID

Servicio de Hematología y Hemoterapia

Active (17/10/2022)

HOSPITAL MD ANDERSON CANCER CENTER MADRID

Madrid

MADRID

Oncología

Active (23/09/2022)

HOSPITAL SAN PEDRO DE ALCANTARA

Cáceres

CÁCERES

Oncología

not initialized (--/--/----)

Hospital San Pedro de Alcantara

Cáceres

CÁCERES

Servicio de Hematología y Hemoterapia

not initialized (--/--/----)

Hospital Universitario Quirónsalud Madrid

Madrid

MADRID

Hematology

Active (17/06/2022)

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID

Pozuelo de Alarcón

MADRID

Oncología

Active (20/09/2022)

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO

Sevilla

SEVILLA

Oncología

not initialized (--/--/----)

Hospital Universitario Virgen del Rocio

Sevilla

SEVILLA

Departamento de Medicina

Active (28/07/2022)

HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE

València

VALENCIA

Oncología

Active (31/05/2022)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Medication

Venclyxto 100 mg film-coated tablets

FILM-COATED TABLET

ORAL

ATC code: L01XX52 - VENETOCLAX

Active Principles: N/A

Experimental

AB8939

POWDER FOR INJECTION

INTRAVENOUS INJECTION

-

Active Principles: N/A

Orphan

Experimental

Vidaza 25 mg/ml powder for suspension for injection

SUSPENSION FOR INJECTION

INTRAVENOUS (IV) OR SUBCUTANEOUS (SC)

ATC code: L01BC07 - AZACITIDINA

Active Principles: N/A

Experimental

No results